Progyny (NASDAQ:PGNY) EVP Sells $10,506.46 in Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 599 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $17.54, for a total transaction of $10,506.46. Following the completion of the sale, the executive vice president directly owned 88,941 shares in the company, valued at approximately $1,560,025.14. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Allison Swartz also recently made the following trade(s):

• On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The shares were sold at an average price of $17.40, for a total value of $81,031.80.
• On Monday, March 2nd, Allison Swartz sold 2,199 shares of Progyny stock. The shares were sold at an average price of $17.27, for a total value of $37,976.73.

Progyny Stock Performance

Shares of PGNY traded up $0.69 during trading hours on Friday, hitting $18.31. The stock had a trading volume of 1,805,320 shares, compared to its average volume of 1,628,731. The firm has a 50-day moving average price of $23.24 and a 200 day moving average price of $22.96. Progyny, Inc. has a fifty-two week low of $16.75 and a fifty-two week high of $28.75. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of 28.17, a PEG ratio of 1.21 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The business had revenue of $318.40 million for the quarter, compared to analyst estimates of $314.26 million. During the same period in the prior year, the company posted $0.42 EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Institutional Trading of Progyny

Institutional investors have recently made changes to their positions in the company. Royal Bank of Canada raised its position in Progyny by 384.8% in the first quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after purchasing an additional 10,340 shares during the period. Amundi boosted its position in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock valued at $5,630,000 after acquiring an additional 14,297 shares during the period. Cetera Trust Company N.A lifted its position in shares of Progyny by 303.1% during the second quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock worth $29,000 after purchasing an additional 985 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Progyny by 357.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 116,138 shares of the company’s stock valued at $2,555,000 after purchasing an additional 90,775 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a research note on Monday, December 29th. Citigroup raised shares of Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Canaccord Genuity Group boosted their price objective on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. Truist Financial lowered their price target on Progyny from $34.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price objective on shares of Progyny in a research note on Friday. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $29.09.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.